晶泰控股-P(02228.HK)擬2.5億元收購上海四維醫學科技90%股權
格隆匯5月11日丨晶泰控股-P(02228.HK)公告，於2025年5月10日，買方深圳晶泰科技有限公司(公司全資附屬公司)、賣方(寧波梅山保稅港區弘睦維投資管理合夥企業、寧波梅山保稅港區弘睦和投資管理合夥企業、上海弘和維醫學科技)、擔保人及目標公司訂立協議，根據該協議，買方已有條件同意購買，而賣方已有條件同意出售目標公司上海四維醫學科技有限公司90%的股權，對價爲人民幣2.5億元，待以現金方式悉數結清。
完成後，買方將於目標公司90%股權中擁有權益。目標集團各成員公司均將成爲本公司的間接非全資附屬公司。
目標公司於2008年成立，爲上海交通大學("上海交通大學")醫學院透過其全資投資平臺上海二醫投資管理有限公司投資的企業，其前身爲上海交通大學醫學院醫學信息遠程監測研發中心，屬高科技企業。目標公司爲中國領先的遠程技術平臺及遠程診斷服務解決方案供應商，亦爲國內最大規模的遠程心電圖診斷服務解決方案企業。依託上海交通大學醫學院支持，目標公司迄今已通過雲計算開放式遠程平臺，爲中國16個省市逾1,700家醫療機構及其服務站點提供包括心電圖、超聲波、血壓及醫學影像平臺與診斷服務解決方案，僅心電圖單項年診斷量已突破1.6百萬人次。
根據《中國心血管健康與疾病報告2023》，心血管疾病已成爲我國城鄉居民首要死亡原因，佔總死亡構成超過45%，高於腫瘤相關死亡率，每5例死亡中就有2例死於心血管疾病。心電監測是提前預防及診斷心血管疾病的重要手段，但在醫療資源配置方面，我國基層醫療機構數量龐大，且普遍面臨心電診斷專業醫師短缺的現狀。
基於此，集團將深度整合自身及目標公司的優勢，通過以下兩個方面來賦能行業發展：1)依託自身在人工智能算法、算力及高質量數據領域的核心優勢，在完成目標公司收購後，將系統性整合目標集團運營積累的心電診斷數據集(包含ECG讀數、超聲影像及心血管參數)，結合集團自主研發的高精度AI輔助診斷系統，打造人工智能賦能的遠程心電診斷平臺。預計可大幅提升醫生看片效率，有效緩解基層醫療心電診斷資源分佈不均的痛點。
2)構建"檢測-診斷-治療"全週期健康管理閉環，基於心電大數據分析挖掘，加速推進心血管創新藥物管線及功能性健康產品的研發進程。通過強化AI藥物開發平臺的技術壁壘，打造將臨牀診斷數據資產轉化爲藥物研發的差異化競爭優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
